BioNTech Shares Jump 8.66% on 186% Surge in Trading Volume to $230M Ranks 474th in Activity

. 5, , . . The momentum followed a key development in the company’s oncology pipeline.

, a next-generation candidate for HER2-positive breast cancer. . , positioning it as a potential advancement in the HER2-targeted therapy space.

Collaboration with China-based Duality Biologics has been central to the trial’s execution. The partnership underscores BioNTech’s strategy to leverage global clinical development networks, particularly in regions with high unmet medical needs. .

To run this precisely we need to pin down a few practical details: 1. ? 2. , or weighted by something else? 3. . . Could you please clarify the above so I can choose the most efficient approach?